The neuroprotective effect of Humanin 10mg is not mediated by a single signaling pathway but by the synergistic action of multi-dimensional mechanisms, focusing on three core aspects: mitochondrial function repair, apoptotic pathway blockage, and oxidative stress regulation. As a mitochondrially derived peptide, its inherent affinity for neuronal mitochondria enables precise targeting of damaged sites, a key characteristic that distinguishes it from traditional neuroprotective agents.

In terms of apoptotic pathway blockage, studies have confirmed that it can inhibit the binding of the pro-apoptotic protein Bax to the mitochondrial membrane by interfering with its functional activity, thereby blocking the caspase cascade reaction triggered by cytochrome C release and reducing neuronal apoptosis. Meanwhile, it upregulates the expression of anti-apoptotic proteins by activating the JAK2/STAT3 signaling pathway, further enhancing the damage resistance of neurons.

In an oxygen-glucose deprivation/reoxygenation (OGD/R) cell model, gradient dilution intervention with the product significantly improved the survival rate and reduced the apoptosis rate of SH-SY5Y neuroblastoma cells. This effect can be reversed by the JAK2 inhibitor FLLL32, confirming the core regulatory role of this pathway.Mitochondrial dysfunction is a major inducer of neuronal damage. The product can repair impaired mitochondrial function by regulating the balance of mitophagy, mitochondrial fission and fusion.

In a rotenone-induced dopamine neuron injury model, pretreatment with this dosage of it downregulated the expression of the mitochondrial fission protein p-DRP1, upregulated the levels of the fusion proteins MFN2 and OPA1 as well as the biogenesis regulatory protein PGC1α, reduced the accumulation of abnormal mitochondria, increased intracellular ATP content, and restored mitochondrial energy supply.In addition, it can alleviate mitochondrial dysfunction caused by excessive activation of NMDA receptors, reduce the production of reactive oxygen species (ROS), and mitigate excitotoxic damage to neurons.

Intervention Potential in Alzheimer's Disease

Alzheimer's disease (AD), the most common neurodegenerative disease, is characterized by core pathological features including β-amyloid (Aβ) deposition, excessive tau phosphorylation, and neuronal loss, for which there is currently no curative treatment. Studies of the product in AD models have shown that it can antagonize Aβ-induced neurotoxicity through multiple mechanisms, providing a new direction for AD therapy.

In animal experiments, it intervention significantly alleviated aβ₁₋₄₂-induced cognitive impairment in rats. Morris water maze tests confirmed that rats in the intervention group had a significantly shortened escape latency and prolonged residence time in the target quadrant. Meanwhile, the number of dendritic branches and spine density of hippocampal neurons increased, and the expression of synaptic proteins was upregulated, improving synaptic plasticity damage.

At the mechanistic level, it can activate protein phosphatase 2A (PP2A) activity by inhibiting the phosphorylation of the PP2A catalytic subunit at the Tyr307 site, thereby reducing excessive tau phosphorylation and the formation of neurofibrillary tangles. Clinical correlation studies found that serum Humanin levels in AD patients are significantly lower than those in healthy individuals.

After hyperbaric oxygen combined with donepezil treatment, serum Humanin levels in patients increased and cognitive function scores improved, suggesting that it can serve as a potential biomarker for AD disease assessment and therapeutic effect evaluation. The 10mg specification provides a standardized experimental basis for such clinical translational research.

Neuroprotective Effect in Parkinson's Disease:Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. PD models induced by toxins such as rotenone and MPTP are commonly used research tools. Research on the application of it in PD models has demonstrated its specific protective effect on dopaminergic neurons and its ability to significantly delay disease progression.In a rotenone-induced PC12 cell model, pretreatment with 20μmol/L it (reconstituted from the 10mg specification) significantly increased cell viability and reduced ROS production.

It also regulated the expression of mitophagy-related proteins, downregulated the levels of Pink1 and p-Parkin as well as the LC3Ⅱ/LC3Ⅰ ratio, reduced the excessive accumulation of autophagosomes, and alleviated mitochondrial damage. In addition, it can enhance cellular antioxidant capacity and mitigate toxin-induced oxidative damage by upregulating the expression of Nrf2 in the antioxidant stress pathway and inhibiting Keap1 activity.This research provides a new target for neuroprotective therapy of PD, and the stability of the 10mg specification enables precise control of experimental doses and ensures the reproducibility of research results.

After the occurrence of ischemic brain injury (e.g., cerebral infarction), excitotoxicity, oxidative stress, and inflammatory responses caused by oxygen-glucose deprivation lead to rapid neuronal death, with extremely high rates of disability and mortality. Studies of Humanin 10mg in ischemic brain injury models have shown that it can alleviate brain tissue damage and improve neurological functional prognosis by targeted regulation of multiple damage pathways.

In the OGD/R model, it can reduce calcium ion influx by inhibiting excessive activation of NMDA receptors, alleviating the damage of excitotoxicity to neurons. It also reduces the levels of ROS and inflammatory factors, mitigating the inflammatory response of brain tissue. In animal experiments, it intervention in rats with cerebral ischemia-reperfusion injury significantly reduced infarct volume, improved neurological deficit scores, decreased the apoptosis rate of neurons in the hippocampus and cerebral cortex, and markedly restored mitochondrial function indicators.

Its mechanism of action is closely related to the activation of the JAK2/STAT3 pathway, mitochondrial function repair, and apoptotic pathway inhibition. The 10mg specification allows flexible adjustment of intervention concentrations according to experimental needs, adapting to different animal models and cell experiment scenarios, and thus serves as a reliable tool for intervention research on ischemic brain injury.

With the deepening of research, its application prospects are broad. On the one hand, based on the standardized characteristics of the 10mg specification, more targeted mechanistic research can be carried out to provide new therapeutic targets for diseases such as neurodegenerative diseases and ischemic brain injury. On the other hand, structural modification can be used to optimize its stability and bioavailability, promoting clinical translational research.

In addition, its potential for combined application with existing therapeutic methods (e.g., drugs, hyperbaric oxygen) is expected to provide new schemes for the comprehensive treatment of neurological diseases. As a research-grade tool, the product will continue to provide core support for basic research and translational applications in the field of neuroprotection.